Chronic Pain and Sex Drive: When the Scans Come Back Clean
Share
The honest answer on chronic pain and sex drive is that the research finds a very large gap between women living with widespread pain and women who are not, and cannot tell you what opened it. The strongest evidence available is a meta-analysis of twelve observational studies covering 1,367 women with fibromyalgia and healthy controls. It reports standardized differences of 1.7 to 2.1 on sexual function, satisfaction, and pain during sex. Those are enormous numbers from a design that can measure a gap without explaining one. It does establish that the flatness you are describing is documented and common among people whose pain never showed up on an image.
- Across 12 observational studies and 1,367 women, 766 with fibromyalgia and 601 healthy controls, sexual function differed by a standardized mean difference of 1.72 (95% CI 1.18 to 2.26, p < 0.001). The reviewers rated those studies moderate in quality on the Newcastle-Ottawa Scale.
- In the same review, the two secondary outcomes that moved most were sexual satisfaction (SMD -2.09, 95% CI -2.83 to -1.36) and pain during sexual relations (SMD -1.97, 95% CI -2.81 to -1.12). Primary and secondary outcomes carry opposite signs because they run in opposite directions on their scales.
- Fibromyalgia is hard enough to count that the pooled global estimate carries almost no precision: 1.40% of the general population, 95% CI 0.49 to 2.47, heterogeneity of 100%, and very low certainty of evidence.
- Pain shows up as an associate of low desire even in women with no pain diagnosis at all. In a community sample of 2,020 women aged 40 to 65, pain during or after intercourse carried odds of 1.63 (95% CI 1.27 to 2.09) for hypoactive sexual desire dysfunction in an adjusted model.
- Every figure on this page comes from observational research. Groups differ, and the design cannot say why. None of it is a diagnosis.
Figures from Ricoy-Cano et al. 2022 (PMID 34262004) and Worsley et al. 2017 (PMID 28499520).
The scans came back and nothing was wrong
This is the sentence that sends people looking. The imaging is clean. The bloodwork is unremarkable. Somebody said the word "normal" in a kind voice, and you went home still hurting, now carrying a second problem on top of the first: the suspicion that you are making it up.
A clean scan is a real result and it answers a narrow question. It tells a clinician that a specific set of things they were looking for are absent. It does not tell them that nothing is happening, because most of what drives widespread, long-running pain does not appear on an image at all. Fibromyalgia has no confirmatory scan and no confirmatory blood test. It is identified by pattern and by exclusion, which is exactly why the counting is so bad.
Researchers have tried to pin down how common it is. D'Souza and colleagues screened 21,645 records and included 882 studies. Their pooled estimate for the general population came out at 1.40%, with a 95% confidence interval running from 0.49% to 2.47%, heterogeneity of 100%, and a certainty rating of very low. Their conclusion says fibromyalgia affects 1% to 2% of the global population and names diagnostic inconsistency as the reason the range is that wide.
So when a clinician cannot find it, that is partly about the condition and partly about the tools. The wider version of this experience is in normal labs and low libido, where the panel comes back fine and the feeling does not.
What twelve studies of women with fibromyalgia found
Ricoy-Cano and colleagues searched six databases through February 2021 for observational studies comparing women diagnosed with fibromyalgia against healthy controls on sexual function. Twelve met the bar, covering 1,367 women, 766 with the diagnosis and 601 without, pooled with Cohen standardized mean differences in a random-effects model.
The primary outcome came out at an SMD of 1.72, with a 95% confidence interval from 1.18 to 2.26 and p < 0.001. Standardized differences describe how far apart two groups sit in units of their own spread, and anything above 0.8 is conventionally called large. This is more than double that.
That size is also why it needs careful handling. Twelve observational studies of moderate methodological quality, in the reviewers' own assessment against the Newcastle-Ottawa Scale, can show that two groups of women answered a questionnaire very differently. They cannot show what made the difference, and they cannot rule out that women recruited into a fibromyalgia study and women recruited as healthy controls differ in ways nobody measured. An effect that large out of a base that small is a prompt to look harder at the design.
Three outcomes from one review, drawn as distance from no difference
Standardized mean differences from Ricoy-Cano et al. 2022, women with fibromyalgia against healthy controls. Dots are the pooled estimate, bars the 95% confidence interval. The abstract signs the primary outcome positive and the two secondary outcomes negative, so all three are drawn here by size of gap.
Source: Ricoy-Cano AJ et al., Journal of Clinical Rheumatology 2022 (PMID 34262004). Random-effects models across 12 observational studies and 1,367 women. Filled dot marks the primary outcome, open dots the secondary outcomes.
All three bars sit clear of the no-difference line, and their intervals are wide too. An interval running from 1.18 to 2.26 says the gap is large and that the studies disagree about how large. That difference matters when somebody quotes 1.72 at you as though it were a measurement of your life.
Where this evidence is solid and where it runs out
Four separate literatures touch this question and they carry very different weight.
| What was studied | The number, with its interval | How much weight it carries |
|---|---|---|
| Fibromyalgia against healthy controls, sexual function | SMD 1.72, 95% CI 1.18 to 2.26, p < 0.001, from 12 studies and 1,367 women | Direction well supported. Size very large and imprecise. Observational, moderate quality, so no mechanism |
| Fibromyalgia, satisfaction and pain during sex | Satisfaction SMD -2.09, 95% CI -2.83 to -1.36. Pain during sexual relations SMD -1.97, 95% CI -2.81 to -1.12 | Same twelve studies, same limits. The outcomes those women reported moving most |
| Long-running pelvic pain with no infection found | Odds of painful sex 11.27, 95% CI 5.15 to 24.67. Total sexual function score mean difference -11.35, 95% CI -14.54 to -8.16, from 9 case-control studies and 4,965 people | Strong association, enormous interval. Five-fold to twenty-five-fold is a signal about direction only |
| Migraine and tension-type headache | No pooled estimate exists. Across 23 observational studies, reported prevalence of sexual difficulty in women ranged from 10.7% to 93.75% | Weakest of the four. A range that wide means the studies measured different populations in different ways |
| Pain as an associate of low desire in women with no pain diagnosis | Odds 1.63, 95% CI 1.27 to 2.09, in an adjusted model from a community sample of 2,020 women aged 40 to 65 | Modest size, tight interval, nationally representative sample, validated instruments. The most transportable finding here |
| A direct route from pain signalling to desire | No pooled estimate exists in any of these reviews | Not established. Every study here compares groups, and that cannot deliver a mechanism |
Everything hurts and I feel nothing
Those two clauses get typed together constantly, and the second confuses people more than the first. Pain is loud. Desire going quiet is silent, and it feels like a personality change you did not agree to.
The Ricoy-Cano review gives that experience its two clearest numbers. Sexual satisfaction moved by a standardized difference of 2.09, on an interval from 1.36 to 2.83. Pain during sexual relations moved by 1.97, interval 1.12 to 2.81. Both come from the same twelve observational studies and carry the same caveats. The reviewers' conclusion lists increased sexual pain and decreased desire or satisfaction among the difficulties women with the diagnosis reported.
Guan and colleagues found the same shape in a different population. Nine case-control studies covering 4,965 people compared women with urologic chronic pelvic pain syndrome, long-running pelvic pain where no infection is found, against healthy controls. Odds of painful sex came out at 11.27, on a 95% confidence interval from 5.15 to 24.67, and total sexual function score differed by a mean of -11.35, interval -14.54 to -8.16. The authors' own reading is careful: psychosocial variables may be a potential pathogenesis, and better designed research is needed.
Both papers support something simpler than a mechanism. A body that has learned to expect pain from an activity stops volunteering for it. That is a sane adaptation, and it needs no hormone to explain it.
I'm exhausted before the day starts
Widespread pain and exhaustion travel together closely enough that people stop trying to separate them. You wake up already spent, ration the day into the two or three things that must get done, and by evening there is nothing left to want anything with.
None of these studies measured energy as an outcome, so anyone giving you a number for it is inventing it. Desire follows capacity, and pain eats capacity first. If the fog and the flatness arrived as a bundle, our piece on brain fog and sex drive takes that bundle seriously, and stress and sex drive covers what a body held in a permanent brace does to wanting.
Pain nobody can see also carries a weight of its own: describing something real and watching somebody decide you have overstated it, again. That load sits separate from the pain and it does not lift on its own. If shame or old harm is part of what you carry into this, low libido, trauma, and shame handles that ground directly.
Headaches belong in this picture too
One systematic review has looked at primary headache, which covers migraine and tension-type headache. Atas and Kaya Mutlu reviewed 23 observational studies published between 2000 and May 2023. Both headache groups scored significantly lower on sexual function than healthy controls in the studies making that comparison, and the authors conclude clinicians should be asking about it. The rest of the paper is harder to use: mean scores ranged from 19.25 to 27.5, and reported prevalence of sexual difficulty in women ranged from 10.7% to 93.75%. No finding has a size inside a range that wide. The review pools nothing and states its own limits.
When the pain has a name
This article is for the reader whose pain has stayed unnamed. Plenty of chronic pain does have a name, and if yours does, the specific page will serve you better.
If your pain is pelvic, cyclical, or has been under investigation for years, start with endometriosis and low sex drive, which works through what the research actually blames. If you already have a rheumatologist and a medication list, autoimmune disease and low sex drive covers lupus, rheumatoid arthritis, and Sjogren's, where the prevalence figures are far higher than most women are ever told.
The mood question gets its own page, and it is kept off this one. Depression and anxiety travel with long-running pain, and they are among the strongest known suppressors of desire in women, which is more than a paragraph here could hold. Depression and low libido covers it in full.
Is this normal, or is it the pain?
Both, and the order of those words matters less than the baseline nobody mentions.
Worsley and colleagues surveyed a nationally representative community sample of 2,020 Australian women aged 40 to 65 using validated instruments. Low desire turned up in 69.3%, on a 95% confidence interval from 67.3 to 71.3. Sexually related personal distress turned up in 40.5%, interval 38.4 to 42.6. The two together, meeting criteria for hypoactive sexual desire dysfunction, came to 32.2%, interval 30.1 to 34.2. That study selected for no condition whatsoever.
So low desire is the common experience of women in this age band, and what a pain condition adds on top of that is a separate question. Worsley's adjusted model is the useful part. Pain during or after intercourse carried odds of 1.63, on a 95% confidence interval from 1.27 to 2.09. Moderate to severe depressive symptoms carried 2.69, interval 1.99 to 3.64. Hot flushes and night sweats carried nothing at all, worth remembering the next time somebody tells you it is your hormones.
Pain shows up as an independent associate of low desire in women never selected for a pain condition. It is a modest effect on a tight interval from a large representative sample, and it is the most transportable finding on this page. Our broader guide, why is my libido so low, walks through the rest of the contributors.
What the pain research explains and what it does not
One question, two very different columns
- Women with fibromyalgia differ from healthy controls on sexual function by 1.72, interval 1.18 to 2.26
- Satisfaction and pain during sex are the outcomes that moved most in that pooled set, at 2.09 and 1.97
- Long-running pelvic pain with no infection found is strongly associated with painful sex, odds 11.27 on a wide interval
- Pain is an associate of low desire even in women carrying no pain diagnosis, odds 1.63 in an adjusted community model
- Fibromyalgia is common and badly counted, 1% to 2% of the population on very low certainty of evidence
- Any mechanism. Every study here compares groups, which cannot deliver a cause
- A precise size for any of it. The intervals on the fibromyalgia effects are roughly one full standardized unit wide
- A prediction about you. Pooled averages describe groups, never an individual
- A ranking of pain against the other things that flatten desire. These reviews measured none of them
- Anything about what changes it. Not one study here tested a treatment, a supplement, or a protocol
Left column from PMID 34262004, PMID 31227839, PMID 28499520, and PMID 42201834. Right column is what those same papers report as absent, unmeasured, or outside their design.
What to take to your doctor
A research summary is a poor substitute for being examined by somebody who knows your history. It can hand you better questions, so the appointment covers ground it would otherwise skip.
- Say the sexual part out loud. The headache reviewers recommend that clinicians ask, and most do not. Raising it yourself is often the only way it enters the conversation.
- Bring dates. When the pain started, when desire changed, in which order. Sequence is information a clinician can use and a memory you will lose if you do not write it down.
- Ask about sleep and daytime exhaustion as their own topic. They get folded into the pain conversation and then never examined.
- Ask what the normal results ruled out. A clean scan answers a specific question, and knowing which one beats being told everything is fine.
- Say the not-being-believed part. If you stopped mentioning symptoms because of how the last conversation went, that belongs in the appointment too. A clinician cannot work with what you edited out.
Bring the research if it helps. A number like 1.72 across twelve studies, with its interval and observational design attached, does the arguing for you. What you are describing is a documented pattern in women who have your diagnosis.
Where desire fits, and where a botanical fits
Everything above is about pain. This part is about desire on its own terms, a separate subject with separate levers.
A few things move desire in most people, pain or no pain, and the free ones do more work than the internet admits. Sleep, in quantity and quality. Care for your mood, with a professional where that fits. Time and safety with a partner, or on your own, because desire responds to a nervous system that is not braced. Movement and food you enjoy. And, if you want one, a botanical supplement as the smallest lever on that list.
NUUD is a botanical supplement built around desire in general. It has nothing to do with pain or fibromyalgia, and no role in managing any pain condition or the care you get for one. The formula is anchored by the NUUD Mushroom Complex™, with Muira Puama, Boiled Rehmannia Root, Tribulus Terrestris, and Piper Nigrum for absorption, on a timeline of roughly 30 to 60 minutes. If the everyday levers are in reasonable shape and you want one more, that is what our women's libido support capsules are for. If pain is running your week, that is a conversation for your doctor and the capsule can wait.
Nothing is wrong with you
You have probably been handed two unhelpful answers already. A shrug from somebody who had eight minutes and no test to run, and a confident voice online telling you exactly what is wrong and exactly what to buy for it.
The research supports neither. It says women living with widespread pain report much lower sexual function, satisfaction, and comfort, at sizes that are large and imprecise, from designs that describe groups. Pain tracks with low desire even in women with no diagnosis. Nobody has demonstrated the route between them. And fibromyalgia is real, common, and so hard to count that the best pooled estimate carries a certainty rating of very low.
None of that is a verdict on you. A clean scan was never proof of anything about your character, and a flat sex drive on top of years of pain is a legible response to circumstances, shared by a lot of people who also got told they looked fine.
Keep reading
- Normal labs, low libido
- Brain fog and sex drive
- Is stress killing your sex drive?
- Low libido, trauma, and shame
- Depression and low libido
- Why is my libido so low?
Frequently asked questions
Does chronic pain lower your sex drive?
The research finds a large and consistent gap and stops short of naming a cause. Ricoy-Cano and colleagues pooled 12 observational studies covering 1,367 women, 766 diagnosed with fibromyalgia and 601 healthy controls, and found a standardized mean difference in sexual function of 1.72 with a 95% confidence interval of 1.18 to 2.26 and p below 0.001. Sexual satisfaction differed by -2.09, interval -2.83 to -1.36, and pain during sexual relations by -1.97, interval -2.81 to -1.12. The reviewers rated those studies moderate in quality, and observational studies compare groups without establishing what created the difference.
Why do I have no sex drive when my scans came back normal?
Because a normal scan answers a narrow question and widespread pain conditions largely do not appear on one. Fibromyalgia has no confirmatory scan and no confirmatory blood test, which is one reason its pooled global prevalence estimate is 1.40% on a 95% confidence interval of 0.49 to 2.47, with heterogeneity of 100% and very low certainty of evidence across 882 included studies. A finding absent from an image tells you what was looked for, and tells you nothing about whether you are hurting. Talk to your doctor about what those normal results ruled out.
Is low sex drive with fibromyalgia normal?
It is common, and low desire is also common in women without any pain condition. In a nationally representative community sample of 2,020 Australian women aged 40 to 65, low desire measured on a validated instrument turned up in 69.3%, sexually related personal distress in 40.5%, and both together in 32.2%. That study selected for no diagnosis at all. Against that baseline, the fibromyalgia literature reports a much larger gap, at a standardized mean difference of 1.72 on an interval of 1.18 to 2.26, from 12 observational studies of moderate methodological quality.
Does the pain itself lower desire, or is it everything around it?
No study on this page can separate those two, and every one of them is observational. What it does show is that pain tracks with low desire in more than one population. In women with long-running pelvic pain where no infection is found, 9 case-control studies covering 4,965 people put the odds of painful sex at 11.27 on a very wide 95% confidence interval of 5.15 to 24.67. In women selected for no condition at all, pain during or after intercourse carried odds of 1.63, interval 1.27 to 2.09, in an adjusted model. Both are associations. Neither is a mechanism.
I just want to feel normal again. Where do I start?
Start with the appointment you have been putting off, and go into it with dates and specifics, since a summary loses the details a clinician can use. Say the sexual part out loud, since the headache reviewers note that clinicians often do not ask. Ask about sleep and daytime exhaustion as their own topic. Ask what the normal results ruled out. Then look at the ordinary levers that move desire in most people: rest, care for your mood, unrushed time, and being in your body without judging it. Nothing is wrong with you for having landed here. Women living with long-running pain report lower sexual function and satisfaction across every study that has looked, and a flat sex drive on top of that load is an understandable response.
References
- Ricoy-Cano AJ, Cortes-Perez I, Del Carmen Martin-Cano M, De La Fuente-Robles YM. Impact of Fibromyalgia Syndrome on Female Sexual Function: A Systematic Review With Meta-analysis. Journal of Clinical Rheumatology. 2022;28(2):e574-e582. https://pubmed.ncbi.nlm.nih.gov/34262004/
- D'Souza RS, Klasova J, Morsi M, et al. The Prevalence of Fibromyalgia in the General Population and At-Risk Subpopulations: A Systematic Review and Meta-Analysis. Anesthesia and Analgesia. 2026. https://pubmed.ncbi.nlm.nih.gov/42201834/
- Guan Y, Yu G, Wang G, Bai Z. The negative effect of urologic chronic pelvic pain syndrome on female sexual function: a systematic review and meta-analysis. International Urogynecology Journal. 2019;30(11):1807-1816. https://pubmed.ncbi.nlm.nih.gov/31227839/
- Atas K, Kaya Mutlu E. Is sexual function impaired in patients with primary headaches? A systematic review of observational studies. Sexual Medicine Reviews. 2025;13(1):94-104. https://pubmed.ncbi.nlm.nih.gov/39385631/
- Worsley R, Bell RJ, Gartoulla P, Davis SR. Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women. The Journal of Sexual Medicine. 2017;14(5):675-686. https://pubmed.ncbi.nlm.nih.gov/28499520/
This article is for general education and is not medical advice. Chronic pain conditions can only be assessed and managed by a licensed clinician, and nothing here is a diagnosis or a treatment plan. NUUD is a botanical supplement with no role in diagnosing, treating, curing, or preventing fibromyalgia, chronic pain, or any other disease, and these statements have not been evaluated by the Food and Drug Administration. Talk with your doctor about your pain, your sleep, and any medication before starting a new supplement.
